Metabolomic Profiling of Blood Plasma in Females with Hyperplasia and Endometrial Cancer.

ABSTRACT: Uterine cancer is the most prevalent gynecologic malignancy in women worldwide. Endometrial cancer (EC) has an 81% five-year survival rate, depending on disease stage and time of diagnosis. While endometrial cancer is largely treatable when detected early, no established screening techniques are available in clinical practice. As a result, one of the most significant issues in the medical field is the development of novel ways for early cancer identification, which could boost treatment success rates. Liquid chromatography-high-resolution mass spectrometry (LC-HRMS)-based metabolomics was employed to explore the metabolomic markers and pathways unique to this cancer type and link them to the benign endometrial hyperplasia that may progress to cancer in 5% to 25% of patients. The study invo

SUBMITTER: Benabdelkamel H 

PROVIDER: S-EPMC10890097 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature